Cellectis (CLLS) Construction in Progress (2022 - 2023)
Cellectis (CLLS) recorded quarterly Construction in Progress of $1.0 million in Q4 2023, down 23.08% quarter-over-quarter from $1.3 million in Q4 2022, and down 23.08% on a YoY basis from $1.3 million in Q4 2022.
Cellectis (CLLS) Construction in Progress (2022 - 2023) Analysis & Trends
Cellectis' Construction in Progress history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2023.
- In Q4 2023, Construction in Progress fell 23.08% year-over-year to $1.0 million; the TTM figure through Dec 2023 stood at $1.0 million (down 23.08% YoY), while the FY2023 annual figure was $1.0 million, down 23.08% from the prior year.
- Construction in Progress was $1.0 million for Q4 2023 at Cellectis, down from $1.3 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $1.3 million in Q4 2022 to a low of $1.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.30 Mn |